BioSpace News Archive

Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2023 financial results before market opening on Thursday, November 2, 2023.

Somerset Pharma, LLC, a leading US-based pharmaceutical company specializing in sterile injectables and ophthalmic products, announces the introduction of Calcium Gluconate 100mg/mL in two sizes, 50mL and 100mL.

Shanghai Junshi Biosciences Co., Ltd announced the presentation of new clinical trial results at the European Society of Oncologists (“ESMO”) Immuno-Oncology Congress 2023, an international conference held in Madrid, Spain, from October 20th to 24th.

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) is pleased to announce that further to its press releases of August 31, 2023, September 22, 2023 and October 19, 2023, Otsuka Pharmaceutical Co., Ltd. (“Otsuka”)

IDEAYA Biosciences, Inc. announced the closing of its underwritten public offering of 5,797,872 shares of its common stock at a public offering price of $23.50 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 319,150 shares of common stock at a public offering price of $23.4999 per pre-funded warrant, before underwriting discounts and commissions.

Coherus BioSciences, Inc., and Shanghai Junshi Biosciences Co., Ltd. announced that the U.S. FDA approved LOQTORZI™ in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy.

DBV Technologies announced that the Company will host a conference call and live audio webcast on Tuesday, October 31st, at 5:00 p.m. ET to review third quarter 2023 financial results and provide a business update.

LumiraDx Limited received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450.

ObsEva SA announced that XOMA will be receiving full worldwide rights on ebopiprant, an investigational, orally active, selective prostaglandin F2α receptor antagonist, following the termination of the license agreement with Organon.

Olympus Corporation has announced a field corrective action in the U.S. to address complaints of adverse events from over insufflation during use of the high-flow insufflation unit UHI-4.